The Department of Health and Social Care announced that puberty blockers will be banned for those under 18 with gender dysphoria in the UK.

The Government announced that, following official medical expert advice, emergency measures prohibiting puberty blocking agents will be extended indefinitely.

The Commission on Human Medicines published an expert opinion that ‘there is currently an unacceptable risk of safety in continuing to prescribe puberty blocking drugs to children.

The Commission recommended that the restrictions be indefinite while efforts are made to ensure children’s and young people’s safety.

1776 Coalition Sponsored Will you join Elon, Vivek and Me? I want gov’t to work for the people, so I joined the DOGE Caucus. Now that Deep State, Establishment & Liberal spenders have a target on me. Fortunately, I’ve got allies like Elon Musk and Vivek Ramaswamy working with me in this mission. This is LTGen Jack Bergman. Please join me in the fight to make gov’t accountable to the citizens..

Wes Streeting, Health and Social Care secretary, said that it is important to “act with caution” and “follow the expert advice” when caring for this vulnerable group’ of young people.

Children’s healthcare should always be based on evidence. He said that the independent expert Commission on Human Medicines determined that current care and prescribing for gender dysphoria or incongruence poses an unacceptable risk to children and young adults.

Dr Cass’s review raised safety concerns about the lack of evidence supporting these medical treatments. When it comes to these vulnerable young people, we need to be cautious and take expert advice.

We are working with NHS England on opening new gender identity services so that people can get the holistic health and well-being support they need.

We will be conducting a clinical study on the use and effectiveness of puberty-blockers in the coming year to provide a solid evidence base.

Dr Hilary Cass who wrote the Cass Review on children’s gender and published her final report last April described puberty blocking drugs as powerful drugs with unproven risks and benefits.

She said: “That’s why I recommended they only be prescribed after a multidisciplinary assessment and within the context of a research protocol.

I support the decision of the government to continue restricting the distribution of puberty blocks for gender dysphoria in areas outside the NHS, where the essential safeguards aren’t being provided.